VRCA,Verrica Pharmaceuticals Inc. | Healthcare

Healthcare

VRCA

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Verrica Pharmaceuticals Inc.VRCA

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.

The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts.

The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Latest News >

Stock Market Highlights: Sensex, Nifty 50 end lower dragged by IT shares, up for third straight week

Jun 8, 2023

Share Market Highlights: BSE Sensex and NSE Nifty 50 ended a volatile session lower on Friday, ending in the red for second session in a row. Losses in IT and FMCG stocks dragged the headline indices lower. Indices, however, have ended higher for the week. The indices, however, recorded minor gains for the week, up for third straight week.

Retail investors back with a bang, pump $2.3 billion into the market in Q4

Jun 9, 2023

In Q4, retail investors in the US showed resilience by investing $2.3 billion in equities despite recession fears. They bought large-cap stocks like Adani, Reliance, SBI, and Ambuja Cement while selling HDFC Bank, Tata Motors, tech stocks, and ITC. FIIs and DIIs also made notable transactions during this period.

Market at close | IT shares drag headline indices lower, Nifty 50 below 18,600

Jun 9, 2023

Hero MotoCorp, Divis Laboratories, Tata Steel, HDFC Life, and Eicher Motors were the top losers on the Nifty 50 while IndusInd Bank, Axis Bank, L&T, Adani Enterprises, and Power Grid Corporation were the top gainers. In terms of sectors, Nifty capital goods climbed 1 percent. However, FMCG, PSU Bank, Information Technology, metal, and oil and gas sectors saw a decline of 0.5-1 percent.

FIIs sell Varun Beverages, Tech Mahindra, buy Manappuram Finance - Stocks that kept dealers busy on Friday

Jun 9, 2023

The flows were mixed with a positive bias at the FII desk and will be impacted by few large block deals. Dealer's suggest that private banks were well bid at FII desk. US Fed outcome and monsoon progress are the key near-term triggers for the domestic market.